MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure

Phase 3
Completed
Conditions
Epilepsy
Epilepsies, Partial
Seizures
First Posted Date
2005-10-03
Last Posted Date
2010-11-15
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
451
Registration Number
NCT00230698

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Phase 2
Terminated
Conditions
Anemia
Aged
Hemoglobins
First Posted Date
2005-09-29
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
9
Registration Number
NCT00228995

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Phase 3
Completed
Conditions
Urinary Tract Infections
Pyelonephritis
First Posted Date
2005-09-29
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
741
Registration Number
NCT00229021

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Phase 3
Completed
Conditions
Erectile Dysfunction
First Posted Date
2005-09-29
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
1116
Registration Number
NCT00229073

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Phase 3
Completed
Conditions
Bacterial Infections and Mycoses
Cholecystitis
Appendicitis
Pancreatitis
Peritonitis
First Posted Date
2005-09-29
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
483
Registration Number
NCT00229060

A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches

Phase 3
Completed
Conditions
Migraine
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
328
Registration Number
NCT00210912

An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.

Phase 3
Completed
Conditions
Migraine
First Posted Date
2005-09-21
Last Posted Date
2011-06-10
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
142
Registration Number
NCT00210860

Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

Phase 2
Terminated
Conditions
Anemia
Interventions
Drug: Placebo
First Posted Date
2005-09-21
Last Posted Date
2014-04-21
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
192
Registration Number
NCT00210626

Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another Erythropoietin

Completed
Conditions
Chronic Renal Failure
Red-Cell Aplasia, Pure
Interventions
Other: No Intervention
First Posted Date
2005-09-21
Last Posted Date
2015-03-24
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
4761
Registration Number
NCT00210951
© Copyright 2025. All Rights Reserved by MedPath